Published in Br J Pharmacol on July 01, 1991
Central kappa-opioid receptor-mediated antidepressant-like effects of nor-Binaltorphimine: behavioral and BDNF mRNA expression studies. Eur J Pharmacol (2007) 1.09
Comparative analysis of the cardioprotective properties of opioid receptor agonists in a rat model of myocardial infarction. Acad Emerg Med (2010) 0.79
Opioid regulation of spinal cord plasticity: evidence the kappa-2 opioid receptor agonist GR89696 inhibits learning within the rat spinal cord. Neurobiol Learn Mem (2007) 0.78
Kappa Opioid Receptor Agonist and Brain Ischemia. Transl Perioper Pain Med (2014) 0.77
U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist. J Pharmacol Exp Ther (1983) 2.65
Effect of lactacidosis on pyridine nucleotide stability during ischemia in mouse brain. J Neurochem (1987) 1.18
CI-977, a novel and selective agonist for the kappa-opioid receptor. Br J Pharmacol (1990) 1.17
Diuretic actions in man of a selective kappa opioid agonist: U-62,066E. J Pharmacol Exp Ther (1987) 1.08
Ischaemic brain damage: the role of excitatory activity and of calcium entry. Br J Anaesth (1985) 1.08
Differential sensitivity of models of antinociception in the rat, mouse and guinea-pig to mu- and kappa-opioid receptor agonists. Br J Pharmacol (1987) 1.00
Pharmacological profile of PD 117302, a selective kappa-opioid agonist. Br J Pharmacol (1987) 0.98
In vivo evidence for spinal delta-opiate receptor operated antinociception. Neuropeptides (1986) 0.97
A novel series of potent and selective agonists at the opioid kappa-receptor. Eur J Pharmacol (1988) 0.97
U-54494A: a unique anticonvulsant related to kappa opioid agonists. J Pharmacol Exp Ther (1987) 0.95
A series of novel, highly potent and selective agonists for the kappa-opioid receptor. Br J Pharmacol (1990) 0.94
MK-801 reduced cerebral ischemic injury by inducing hypothermia. Brain Res (1990) 0.94
The anticonvulsant action of CI-977, a selective kappa-opioid receptor agonist: a possible involvement of the glycine/NMDA receptor complex. Eur J Pharmacol (1990) 0.92
Beneficial effects of the kappa opioid receptor agonist U-50488H in experimental acute brain and spinal cord injury. Brain Res (1987) 0.85
Quantitative analysis of effects of kappa-opioid agonists on postischemic hippocampal CA1 neuronal necrosis in gerbils. Stroke (1988) 0.83
Evidence that endogenous enkephalins and a delta opioid receptor agonist have a common site of action in spinal antinociception. Eur J Pharmacol (1988) 0.81
Effect of iopanoic acid on basal and thyrotropin-stimulated thyroid hormone levels in suckling rat pups. Life Sci (1990) 0.79
Protection from ischemia-induced cerebral edema in the rat by U-50488H, a kappa opioid receptor agonist. Brain Res (1987) 0.79
Treatment of stroke with opiate antagonists--effects of exogenous antagonists and dynorphin 1-13. Neuropeptides (1985) 0.79
Protection from cerebral ischemia by U-50,488E, a specific kappa opioid analgesic agent. Life Sci (1985) 0.78
Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. Psychopharmacol Bull (1988) 2.50
Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature (1988) 2.42
PILONIDAL SINUS: OBSERVATIONS ON ONE HUNDRED FORTY CASES TREATED BY CAUTERY EXCISION. Ann Surg (1938) 2.05
Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptors. Br J Pharmacol (1988) 1.96
A classification of opiate receptors that mediate antinociception in animals. Br J Pharmacol (1980) 1.95
RECAP--retrosynthetic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry. J Chem Inf Comput Sci (1998) 1.79
Pharmacological characterization of 5-hydroxytryptamine-induced depolarization of the rat isolated vagus nerve. Br J Pharmacol (1987) 1.77
Rapid and extensive surface changes near Titan's equator: evidence of April showers. Science (2011) 1.56
The influence of psychotropic drugs on aldole, mitochondrial malic dehydrogenase and Mg++na+K+ adenosine triphosphatase. Br J Pharmacol (1969) 1.44
5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. Br J Pharmacol (1989) 1.42
Modified-peptide inhibitors of amyloid beta-peptide polymerization. Biochemistry (1999) 1.40
"Selectivity" and "specificity": what do they mean? Gen Pharmacol (1993) 1.40
Long-term biomedical and psychosocial outcomes following DAFNE (Dose Adjustment For Normal Eating) structured education to promote intensive insulin therapy in adults with sub-optimally controlled Type 1 diabetes. Diabetes Res Clin Pract (2010) 1.38
Where now? The anaesthetist's development in management. Anaesthesia (1993) 1.38
Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur J Pharmacol (1988) 1.37
Development of specific tests for rapid detection of Escherichia coli and all species of Proteus in urine. J Clin Microbiol (1977) 1.32
Binding of the 5-HT3 ligand, [3H]GR65630, to rat area postrema, vagus nerve and the brains of several species. Eur J Pharmacol (1989) 1.29
Methyl mercaptan and dimethyl disulfide production from methionine by Proteus species detected by head-space gas-liquid chromatography. J Clin Microbiol (1977) 1.28
6,7-Dinitro-quinoxaline-2,3-dion and 6-nitro,7-cyano-quinoxaline-2,3-dion antagonise responses to NMDA in the rat spinal cord via an action at the strychnine-insensitive glycine receptor. Eur J Pharmacol (1988) 1.27
The pharmacological characterization of 5-HT3 receptors in three isolated preparations derived from guinea-pig tissues. Br J Pharmacol (1990) 1.27
The non-peptide NK1 receptor antagonist, (+/-)-CP-96,345, produces antinociceptive and anti-oedema effects in the rat. Br J Pharmacol (1992) 1.27
A phase II study of ifosfamide in children with recurrent solid tumours. Cancer Chemother Pharmacol (1985) 1.24
What do stroke patients and their carers want from community services? Fam Pract (2005) 1.18
Antiemetic properties of the 5HT3-receptor antagonist, GR38032F. Cancer Treat Rev (1987) 1.17
Influence of atmospheric CO2 enrichment, soil N, and water stress on needle surface wax formation in Pinus palustris (Pinaceae). Am J Bot (1997) 1.16
Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat. Proc Natl Acad Sci U S A (1996) 1.15
The pharmacology of AH8165: a rapid-acting, short-lasting, competitive neuromuscular blocking drug. Br J Anaesth (1973) 1.14
Increasing breastfeeding rates to reduce infant illness at the community level. Pediatrics (1998) 1.13
The potential anxiolytic activity of GR38032F, a 5-HT3-receptor antagonist. Br J Pharmacol (1988) 1.11
Effect of the 5-HT3 receptor antagonist, GR38032F, on responses to injection of a neurokinin agonist into the ventral tegmental area of the rat brain. Eur J Pharmacol (1987) 1.09
5-HT3 receptors mediate inhibition of acetylcholine release in cortical tissue. Nature (1989) 1.08
Head-space gas-liquid chromatography for the rapid laboratory diagnosis of urinary tract infections caused by enterobacteria. J Chromatogr (1983) 1.07
Birth certificate revision and reporting of congenital malformations. Am J Public Health (1974) 1.07
GR127935: a potent and selective 5-HT1D receptor antagonist. Behav Brain Res (1996) 1.07
Determination of receptors that mediate opiate side effects in the mouse. Br J Pharmacol (1983) 1.06
The psychopharmacology of 5-HT3 receptors. Pharmacol Ther (1990) 1.06
Agonist effects of [D-Pro2,D-Phe7,D-Trp9]substance P--evidence for different receptors. Eur J Pharmacol (1982) 1.05
Single-dose pharmacokinetic and pharmacodynamic comparison of polymer-matrix (Slow Trasicor) and Oros dosage forms of oxprenolol in healthy volunteers. Br J Clin Pharmacol (1985) 1.05
Multifocal multiphoton excitation and time correlated single photon counting detection for 3-D fluorescence lifetime imaging. Opt Express (2007) 1.05
The neuromuscular blocking action of 2-(4-phenylpiperidino) cyclohexanol (AH 5183). Eur J Pharmacol (1969) 1.05
Unlocking the blood-brain barrier: a role for RMP-7 in brain tumor therapy. Exp Neurol (1996) 1.04
Calpain inhibitor AK295 protects neurons from focal brain ischemia. Effects of postocclusion intra-arterial administration. Stroke (1994) 1.04
The distribution of specific binding of the 5-HT3 receptor ligand [3H]GR65630 in rat brain using quantitative autoradiography. Neurosci Lett (1988) 1.03
Premenopausal women with idiopathic low-trauma fractures and/or low bone mineral density. Osteoporos Int (2011) 1.03
Further studies on opiate receptors that mediate antinoception: tooth pulp stimulation in the dog. Br J Pharmacol (1980) 1.02
Defined dimensional changes in enzyme cofactors: fluorescent "stretched-out" analogs of adenine nucleotides. Science (1977) 1.02
Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7. Exp Neurol (1996) 1.02
Assessment of technique for rapid detection of Escherichia coli and Proteus species in urine by head-space gas-liquid chromatography. J Clin Microbiol (1977) 1.01
Perivesical fat necrosis after adjuvant intravesical chemotherapy. BJU Int (1999) 1.01
Calpain as a novel target for treating acute neurodegenerative disorders. Neurol Res (1995) 1.01
Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmacol (1987) 1.01
5-HT3 receptors. Med Res Rev (1990) 1.01
The effect of GR38032F, novel 5-HT3-receptor antagonist on gastric emptying in the guinea-pig. Br J Pharmacol (1987) 1.00
Differential sensitivity of models of antinociception in the rat, mouse and guinea-pig to mu- and kappa-opioid receptor agonists. Br J Pharmacol (1987) 1.00
Norbinaltorphimine: antagonist profile at kappa opioid receptors. Eur J Pharmacol (1987) 1.00
The importance of prolonged incubation for the synthesis of dimethylnitrosamine by enterobacteria. J Med Microbiol (1976) 1.00
Influence of 5-hydroxytryptamine uptake on the apparent 5-hydroxytryptamine antagonist potency of metoclopramide in the rat isolated superior cervical ganglion. Br J Pharmacol (1987) 0.99
Using cultural knowledge in health promotion: breastfeeding among the Navajo. Health Educ Behav (1997) 0.98
A hyperspectral fluorescence lifetime probe for skin cancer diagnosis. Rev Sci Instrum (2007) 0.98
Evolution of a novel series of [(N,N-dimethylamino)propyl]- and piperazinylbenzanilides as the first selective 5-HT1D antagonists. J Med Chem (1994) 0.98
The role of 5-HT in postoperative nausea and vomiting. Br J Anaesth (1992) 0.97
Spontaneous elimination of inhaled inflorescence presenting as dorsal tumour. Br Med J (1966) 0.97
Ondansetron inhibits a behavioural consequence of withdrawing from drugs of abuse. Pharmacol Biochem Behav (1990) 0.96
Evoked potentials during isoflurane anaesthesia. Br J Anaesth (1986) 0.95
Rapid Identification of Cl. welchii by the Nagler Reaction. Br Med J (1941) 0.95
Intravenous RMP-7 selectively increases uptake of carboplatin into rat brain tumors. Cancer Res (1996) 0.95
Dimensional probes of the enzyme binding sites of adenine nucleotides. Biological effects of widening the adenine ring by 2.4 A. Biochemistry (1978) 0.95
Sustained release hGH microsphere formulation produced by a novel supercritical fluid technology: in vivo studies. J Control Release (2009) 0.95
Kynurenate and FG9041 have both competitive and non-competitive antagonist actions at excitatory amino acid receptors. Eur J Pharmacol (1988) 0.95
Human pharmacokinetics of acyclovir (an antiviral agent) following rapid intravenous injection. J Antimicrob Chemother (1981) 0.94
A series of novel, highly potent and selective agonists for the kappa-opioid receptor. Br J Pharmacol (1990) 0.94
Inter-species variants of the 5-HT3 receptor. Biochem Soc Trans (1992) 0.94
Effects of capsaicin on nociceptive heat, pressure and chemical thresholds and on substance P levels in the rat. Brain Res (1980) 0.92
The non-collagenous proteins of the human intervertebral disc. Gerontologia (1969) 0.92
Pancam multispectral imaging results from the Opportunity Rover at Meridiani Planum. Science (2004) 0.91
Sites of action of ondansetron to inhibit withdrawal from drugs of abuse. Pharmacol Biochem Behav (1990) 0.90
GR159897, a potent non-peptide antagonist at tachykinin NK2 receptors. Eur J Pharmacol (1995) 0.90
[3H] GR67330, a very high affinity ligand for 5-HT3 receptors. Naunyn Schmiedebergs Arch Pharmacol (1990) 0.90
Antinociceptive actions of morphine and buprenorphine given intrathecally in conscious rats [proceedings]. Br J Pharmacol (1979) 0.90
Pharmacology of delta-opioid receptors in the hamster vas deferens. Eur J Pharmacol (1986) 0.89
Late results of laminectomy for lumbar disc prolapse. A review after ten to twenty-five years. J Bone Joint Surg Br (1974) 0.89
Effect of 5-HT3 receptor antagonists on responses to selective activation of mesolimbic dopaminergic pathways in the rat. Br J Pharmacol (1990) 0.88
The depolarising action of capsaicin on rat isolated sciatic nerve. Life Sci (1984) 0.88
Sepsis: the critical role of iron. Microbes Infect (2000) 0.88
Determination of the receptor selectivity of opioid agonists in the guinea-pig ileum and mouse vas deferens by use of beta-funaltrexamine. Br J Pharmacol (1985) 0.88
Evidence that the amygdala is involved in the disinhibitory effects of 5-HT3 receptor antagonists. Psychopharmacology (Berl) (1991) 0.87